{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:46:20Z","timestamp":1791773180202,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.thromres.2026.109722","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:03:46Z","timestamp":1779984226000},"page":"109722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["DOACs in cirrhosis: Progress, pitfalls, and the path forward"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-1995","authenticated-orcid":false,"given":"Alexa","family":"Loncharich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.thromres.2026.109722_bb0005","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.cgh.2024.08.020","article-title":"Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis","volume":"23","author":"Zamani","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1478-3231.2011.02517.x","article-title":"All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study","volume":"32","author":"Fleming","year":"2012","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2025.05.013","article-title":"Cause-specific mortality in patients with steatotic liver disease in the United States","volume":"83","author":"Ochoa-Allemant","year":"2025","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109722_bb0025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3109\/00365528309182110","article-title":"Main causes of death in cirrhosis","volume":"18","author":"Schlichting","year":"1983","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109722_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"15","key":"10.1016\/j.thromres.2026.109722_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008703","article-title":"Liver disease as a predictor of new-onset atrial fibrillation","volume":"7","author":"Huang","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/apt.17368","article-title":"Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension","volume":"57","author":"Vandenberk","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.thromres.2026.109722_bb0050","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/liv.13459","article-title":"Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population-based study","volume":"37","author":"Lee","year":"2017","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.thromres.2026.109722_bb0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4330\/wjc.v12.i7.342","article-title":"Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis","volume":"12","author":"Darrat","year":"2020","journal-title":"World J. Cardiol."},{"issue":"11","key":"10.1016\/j.thromres.2026.109722_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2026.109722_bb0065","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2026.109722_bb0070","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2026.109722_bb0075","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2026.109722_bb0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2026.109722_bb0085","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral Rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.thromres.2026.109722_bb0090","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2026.109722_bb0095","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2026.109722_bb0100","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"10","key":"10.1016\/j.thromres.2026.109722_bb0105","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"issue":"12","key":"10.1016\/j.thromres.2026.109722_bb0115","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.thromres.2026.109722_bb0125","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.thromres.2026.109722_bb0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0135","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026863","article-title":"Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation","volume":"12","author":"Simon","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2026.109722_bb0145","article-title":"Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","volume":"10","author":"Chang","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.thromres.2026.109722_bb0150","article-title":"Contemporary trends and barriers to oral anticoagulation therapy in non-valvular atrial fibrillation during DOAC predominant era","volume":"46","author":"Sehrawat","year":"2023","journal-title":"Int. J. Cardiol. Heart. Vasc."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled- analysis of >20 000 patients","volume":"8","author":"Chen","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.dld.2018.12.001","article-title":"Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis","volume":"51","author":"Chokesuwattanaskul","year":"2019","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40256-019-00369-x","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"20","author":"Fu","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0170","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40256-023-00598-1","article-title":"Direct oral anticoagulants versus vitamin K antagonists in cirrhotic patients with atrial fibrillation: update of systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0175","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10557-020-07065-y","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"35","author":"Huang","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0185","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13397","article-title":"Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102534","article-title":"Efficacy and safety of direct oral anticoagulants compared to vitamin K antagonists for atrial fibrillation in patients with liver cirrhosis: an update systematic review and meta-analysis","volume":"15","author":"Miranda","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo","year":"2023","journal-title":"Clin. Exp. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.thromres.2026.109722_bb0205","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study","volume":"177","author":"Simon","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.thromres.2026.109722_bb0210","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.thromres.2026.109722_bb0215","article-title":"Comparison of apixaban, rivaroxaban, dabigatran, and vitamin K antagonists in patients with atrial fibrillation and liver disease: a network meta-analysis","volume":"16","author":"Shaikh","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.thromres.2026.109722_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros","year":"2024","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2026.109722_bb0225","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH","volume":"22","author":"Carlin","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann. Thorac. Surg."},{"issue":"9689","key":"10.1016\/j.thromres.2026.109722_bb0235","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0245","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/europace\/euad004","article-title":"Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States National Cohort Study","volume":"25","author":"Mir","year":"2023","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.thromres.2026.109722_bb0250","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.hrthm.2022.04.009","article-title":"Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation","volume":"19","author":"Thotamgari","year":"2022","journal-title":"Heart Rhythm."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.hrthm.2025.05.021","article-title":"Ablation of atrial fibrillation and risk of stroke: a meta- analysis","volume":"23","author":"Providencia","year":"2026","journal-title":"Heart Rhythm."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jce.16472","article-title":"Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis","volume":"36","author":"Barrera","year":"2025","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109722_bb0270","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.2020006827","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"137","author":"Valeriani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0280","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.mcna.2025.01.007","article-title":"Venous thromboembolism in unusual locations","volume":"109","author":"Afzal","year":"2025","journal-title":"Med. Clin. North Am."},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0285","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ejh.14363","article-title":"Direct oral anticoagulants in Budd-Chiari syndrome","volume":"114","author":"Thapa","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0290","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0039-1679934","article-title":"Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis","volume":"39","author":"Weinberg","year":"2019","journal-title":"Semin. Liver Dis."},{"issue":"8","key":"10.1016\/j.thromres.2026.109722_bb0295","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.cgh.2023.04.016","article-title":"Bleeding and thrombotic complications in patients with cirrhosis: a state-of-the-art appraisal","volume":"21","author":"Rautou","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.thromres.2026.109722_bb0300","doi-asserted-by":"crossref","first-page":"662","DOI":"10.14423\/SMJ.0000000000001750","article-title":"Efficacy and safety of direct oral anticoagulants compared to warfarin in patients with cirrhosis and splanchnic vein thrombosis","volume":"117","author":"Prince","year":"2024","journal-title":"South. Med. J."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0305","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA clinical practice update on management of portal vein thrombosis in patients with cirrhosis: expert review","volume":"168","author":"Davis","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0310","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jhep.2025.06.035","article-title":"Rivaroxaban to prevent complications of portal hypertension in cirrhosis: the CIRROXABAN study","volume":"83","author":"Puente","year":"2025","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0315","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s12072-021-10233-3","article-title":"A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?","volume":"15","author":"Dong","year":"2021","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0320","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0325","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s12072-021-10247-x","article-title":"A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis","volume":"15","author":"Ng","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.thromres.2026.109722_bb0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.thromres.2023.06.003","article-title":"Direct oral anticoagulants for the treatment of splanchnic vein thrombosis - a systematic review and meta-analysis","volume":"229","author":"Li","year":"2023","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14520","article-title":"Meta-analysis and systematic review: prevalence, graft failure, mortality, and post-operative thrombosis in liver transplant recipients with pre-operative portal vein thrombosis","volume":"36","author":"Yeo","year":"2022","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.thromres.2026.109722_bb0340","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.thromres.2026.109722_bb0345","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2026019823","article-title":"Direct oral anticoagulants in portal vein thrombosis in cirrhotic patients: a systematic review and meta-analysis","author":"Boccatonda","year":"2026","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103296","article-title":"Safety and efficacy of direct oral anticoagulants in patients with liver cirrhosis: a meta-analysis","volume":"10","author":"Tham","year":"2026","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0355","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/17843286.2022.2108259","article-title":"Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis","volume":"78","author":"Zhao","year":"2023","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.thromres.2026.109722_bb0360","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241301402","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin in cirrhotic patients: a systematic review and meta-analysis","volume":"30","author":"Cheng","year":"2024","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2026.109722_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109103","article-title":"Impact of anticoagulation therapy on outcomes in patients with cirrhosis and portal vein thrombosis: a large-scale retrospective cohort study","volume":"241","author":"Niu","year":"2024","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100052","article-title":"Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis","volume":"7","author":"Lisman","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2026.109722_bb0375","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/MEG.0000000000002787","article-title":"A pilot study of safety and efficacy comparison of low molecular heparin calcium sequential oral anticoagulants in the treatment of cirrhotic portal vein thrombosis","volume":"36","author":"Zhang","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.thromres.2026.109722_bb0380","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2024.04.002","article-title":"Apixaban for the treatment of acute splanchnic vein thrombosis: a pilot study","volume":"237","author":"Kim","year":"2024","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0385","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/rth2.12480","article-title":"Direct oral anticoagulants for unusual-site venous thromboembolism","volume":"5","author":"Riva","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0390","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0395","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109722_bb0400","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00261-022-03411-w","article-title":"Interventional recanalization therapy in patients with non- cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access","volume":"47","author":"Mansour","year":"2022","journal-title":"Abdom. Radiol. (NY)"},{"issue":"12","key":"10.1016\/j.thromres.2026.109722_bb0405","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/MEG.0000000000001559","article-title":"Escalating interventional recanalization therapy in non- cirrhotic, non-malignant acute portal vein thrombosis","volume":"31","author":"Gerwing","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/a-1642-0990","article-title":"Portal vein thrombosis: diagnosis and endovascular management","volume":"194","author":"Ju","year":"2022","journal-title":"Rofo"},{"issue":"7","key":"10.1016\/j.thromres.2026.109722_bb0415","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.14309\/ajg.0000000000001194","article-title":"Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study","volume":"116","author":"Lv","year":"2021","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0420","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","author":"Villa","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0425","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2012.04.004","article-title":"EASL Clinical Practice Guidelines on vascular diseases of the liver","volume":"84","author":"European Association for the Study of the Liver","year":"2026","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0430","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"9828","key":"10.1016\/j.thromres.2026.109722_bb0435","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0440","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"Sogaard","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0445","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/hep.32019","article-title":"Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nation-wide cohort study","volume":"74","author":"Jepsen","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0450","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.thromres.2026.109722_bb0455","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0460","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0465","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.thromres.2026.109722_bb0470","first-page":"479","article-title":"Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis","volume":"37","author":"Jones","year":"2020","journal-title":"Fed. Pract."},{"issue":"2","key":"10.1016\/j.thromres.2026.109722_bb0475","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11239-019-02035-0","article-title":"Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes","volume":"50","author":"Davis","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0480","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/10600280211025050","article-title":"Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study","volume":"56","author":"Coons","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"1563","key":"10.1016\/j.thromres.2026.109722_bb0485","first-page":"52","article-title":"Bleeding risk of oral anticoagulants in liver cirrhosis","volume":"135","author":"Munevar Aquite","year":"2022","journal-title":"N. Z. Med. J."},{"issue":"7","key":"10.1016\/j.thromres.2026.109722_bb0490","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/10600280211047433","article-title":"Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis","volume":"56","author":"Oldham","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.thromres.2026.109722_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102293","article-title":"Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin","volume":"8","author":"Lawal","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109722_bb0500","series-title":"Clinical guides - portal vein thrombosis","author":"Thrombosis Canada","year":"2026"},{"issue":"6","key":"10.1016\/j.thromres.2026.109722_bb0505","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.thromres.2026.109722_bb0510","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109722_bb0515","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:36:10Z","timestamp":1781166970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"alternative-id":["S0049384826001416"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109722","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DOACs in cirrhosis: Progress, pitfalls, and the path forward","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109722"}}